These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18534821)

  • 1. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
    Meyer JM; Davis VG; McEvoy JP; Goff DC; Nasrallah HA; Davis SM; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Aug; 103(1-3):104-9. PubMed ID: 18534821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What CATIE found: results from the schizophrenia trial.
    Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
    Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
    Ramsey TL; Brennan MD
    Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
    World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
    Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
    Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.
    Newcomer JW; Ratner RE; Eriksson JW; Emsley R; Meulien D; Miller F; Leonova-Edlund J; Leong RW; Brecher M
    J Clin Psychiatry; 2009 Apr; 70(4):487-99. PubMed ID: 19358783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; Srisurapanont M; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006625. PubMed ID: 20091600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
    Volavka J; Czobor P; Citrome L; Van Dorn RA
    CNS Spectr; 2014 Oct; 19(5):374-81. PubMed ID: 24284234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting the results of the CATIE study.
    Lieberman JA; Hsiao JK
    Psychiatr Serv; 2006 Jan; 57(1):139. PubMed ID: 16399980
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
    Mohamed S; Rosenheck RA; Lin H; Swartz M; McEvoy J; Stroup S
    J Nerv Ment Dis; 2015 Jul; 203(7):486-92. PubMed ID: 26075840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
    McEvoy JP; Lieberman JA; Stroup TS; Davis SM; Meltzer HY; Rosenheck RA; Swartz MS; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
    Am J Psychiatry; 2006 Apr; 163(4):600-10. PubMed ID: 16585434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting the results of the CATIE study.
    Pandiani JA; Banks SM
    Psychiatr Serv; 2006 Jan; 57(1):140-1. PubMed ID: 16399981
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
    Correll CU; Manu P; Olshanskiy V; Napolitano B; Kane JM; Malhotra AK
    JAMA; 2009 Oct; 302(16):1765-73. PubMed ID: 19861668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.